J&J/Bayer's anticoagulant Xarelto gets US panel nod
This article was originally published in Scrip
Executive Summary
A US FDA advisory panel has endorsed Johnson & Johnson/Bayer's oral anticoagulant Xarelto (rivaroxaban) for the short-term prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, despite liver safety questions.